Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.
D000111:Acetylcysteine / Q000627:therapeutic use*; D000171:Acrolein / Q000378:metabolism; D000230:Adenocarcinoma / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003520:Cyclophosphamide / Q000031:analogs & derivatives*; D003556:Cystitis / Q000139:chemically induced / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006417:Hematuria / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects* / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy*
D000171:Acrolein; D003520:Cyclophosphamide; D007069:Ifosfamide; D000111:Acetylcysteine